Sort   by:  
 Page size 
UnknownThe use of nanobodies in a sensitive ELISA test for SARS-CoV-2 Spike 1 protein.
Not available
S-EPMC8483265 | biostudies-literature
UnknownAlternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial.
Not available
S-EPMC8905684 | biostudies-literature
UnknownNeutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago.
Not available
S-EPMC8646600 | biostudies-literature
UnknownBreadth and function of antibody response to acute SARS-CoV-2 infection in humans.
Not available
S-EPMC8130932 | biostudies-literature
UnknownStructures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
Not available
S-EPMC8690919 | biostudies-literature
UnknownA potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19.
Not available
S-EPMC8458290 | biostudies-literature
UnknownHypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells.
Not available
S-EPMC8020087 | biostudies-literature
UnknownTwo doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.
Not available
S-EPMC8371089 | biostudies-literature
UnknownThe mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.
Not available
S-EPMC4262609 | biostudies-literature
UnknownT-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study.
Not available
S-EPMC8577846 | biostudies-literature
Sort   by:  
 Page size